TB-500Check methods and identity
What mass spectrometry detected as TB-500 broke down
2 numbered sourcesSource years 2024, 2026
Amino acids joined by peptide bonds form short chains called peptides. An enzyme can cut one of those bonds, leaving fragments whose properties may differ from those of the whole chain. TB-500 is an acetylated seven-amino-acid fragment of thymosin beta-4. In an older 2024 study, researchers asked which shorter molecules appeared after it was broken down and whether those molecules could be measured separately. [1]
The investigators developed a method that combines liquid chromatography and mass spectrometry. One measurement helps separate different molecules in a mixture, and another helps identify each one. Reference substances let scientists check that a signal represents the substance they think it does. This distinction is useful when several related molecules appear together. This helped them assign signals to individual breakdown products in laboratory experiments and in samples from rats. [1]
One prominent product in the rat samples was Ac-LK, an acetylated two-amino-acid fragment. The researchers also compared the parent peptide and some fragments in a cell assay that tracked how fibroblasts move into open space. The FDA's 2026 briefing noted that intact TB-500 did not produce a significant change in that specific assay, while one metabolite produced a small difference. Results for one set of culture conditions leave open what other cells and measures might show. [1] [2]
Detection establishes that a compound was present in a sample. An activity assay asks what the compound does under defined conditions. The two measurements complement each other because a fragment can be abundant and have little activity in one test, or it can be less abundant and matter for another outcome. This study measured both types of evidence in nonclinical settings. [1] [2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Khandoker Asiqur Rahaman et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B (publication 2024-02-07). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
- 2.U.S. Food and Drug Administration. July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate). U.S. Food and Drug Administration (publication 2026-07). (opens in a new tab)
fda.gov↩ Back to text
